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The approach to early Parkinson’s disease denotes the communication of the diagnosis and important decisions,
such as when and how to start treatment. Evidence based medicine and guidelines indicate which drugs have
robust evidence of efficacy and tolerability in this specific population. However, de-novo patients may show
different characteristics and they may be in a different phase of their disease.
In this review, we will give an insight into the appropriate time therapy should be started and the actual
knowledge about disease modification therapies. Moreover, the drugs indicated for early treatment will be
considered and an indication for the use of these drugs will be given with the support of the actual knowledge.Introduction
The approach to early Parkinson’s disease denotes the
communication of the diagnosis and important decisions,
such as when and how to start treatment. Evidence based
medicine and guidelines indicate which drugs have robust
evidence of efficacy and tolerability in this specific
population. However, de-novo patients may show differ-
ent characteristics and they may be in a different phase
of their disease.
The treatment of patients with early Parkinson’s disease
should aim to slow down clinical progression, control
motor and non-motor symptoms, maintain functioning in
daily-life activities, prevent motor complications and
minimize the risk of side effects.
In this review the drugs indicated for early treatment
will be considered and an indication for the use of these
drugs will be given with the support of the actual
knowledge.
When to start treatment
Parkinson’s disease (PD) is a progressive neurodegenerative
disorder that is manifested clinically by a resting tremor,
rigidity and bradykinesia. These typical motor symptoms
are due to the degeneration and loss of dopaminergic neu-
rones in the substantia nigra with consequent reduction in
the ability of the brain to form, store and regulate the* Correspondence: fabrizio.stocchi@fastwebnet.it
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unless otherwise stated.release of dopamine, which is essential for the control of
motor function [1].
The rate of disease progression varies in the early
stages, being slower in the less affected patients. In the
placebo cohort of the ADAGIO trial, a significant correl-
ation between rate of progression and baseline UPDRS
score was found. Patients in the placebo group with the
highest quartile of baseline total UPDRS scores (>25 · 5;
n = 145) had the greatest rate of progression (change
from baseline to 36 weeks of 6 · 0 units [SD 8 · 4]) with a
rate of decline of about 9 UPDRS points per year. In
contrast, patients with the lowest quartile of baseline
UPDRS scores (≤14; n = 160) deteriorated between baseline
and week 36 by 2 · 5 units (SD 4 · 8), with an extrapolated
rate of deterioration of about 4 units per year. The differ-
ence in the progression from baseline to week 36 (last
observed value) between the two quartiles was significant
(mean difference −3 · 46 [SE 0 · 77]; p < 0 · 0001) [2]. Thus
the early period after diagnosis is critical in terms of rate of
progression, but it is also in the early stage of the disease
that an intervention able to modify the natural course of
the disease may be more successful.
Today there is a large debate about the opportunity to
start pharmacological treatment as soon as the disease
manifests.
Until now, the recommendation that drug treatment
should be delayed until the symptoms of PD significantly
limited the patient’s motor functions has become estab-
lished in teaching and part of many guidelines. The ration-
ale for this was to protect the patients from unnecessary. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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ated with levodopa. Moreover, a view also evolved that
patients delaying the introduction of pharmacological
treatment would respond for longer when the drugs were
introduced. Despite the fact that there is no evidence
supporting this theory, the majority of clinicians follow it.
Bearing in mind that the denervation in PD begins
approximately 6 years before the appearance of symptoms,
basal ganglia have a remarkable capacity to cope with
progressively low levels of dopamine activating compensa-
tory mechanisms. The appearance of symptoms indicates
the point of failure to deal adequately with dopamine
depletion. Recently, A. Schapira and J. Obeso proposed
that the early restoration of basal ganglia physiology
would support the compensatory events and delay the
irreversible modification of circuitry that characterizes the
clinical progression of PD [3]. However, the theory of an
early compensatory effect of symptomatic drug with an
associated better long-term symptom control is fascinat-
ing and we believe it is time to reconsider the traditional
view of starting symptomatic treatment as late as possible.
Slowing down clinical progression: where we are
While there have been many promising candidate agents
based on laboratory studies and pathologic findings, no
treatment has as yet been established to have neuropro-
tective or disease-modifying properties in PD. Several
obstacles have been identified that impede the achieve-
ment of this goal [4].
The cause of PD
A number of pathogenic factors have been implicated, in-
cluding oxidative stress, mitochondrial dysfunction, inflam-
mation, excitotoxicity, and signals mediating an apoptosis
cascade [1,5]. Several environmental factors have been
identified as risk factors, as well as a number of gene muta-
tions [6-8] but none these factors seem to be determinant
in sporadic cases. At present, it seems likely that sporadic
cases are due to a complex interaction between environ-
mental, genetic and epigenetic factors [9].
Animal model
The 6-OHDA rodent, MPTP mouse and primate models
of PD [10,11] are caused by the acute administration of
toxins that likely do not reflect the etio-pathogenesis of
PD; they do not accurately reflect the pathologic distribu-
tion of the disease. Transgenic models based on genetic
causes of PD are more promising [12].
Clinical trials target validation, scales and biomarkers
If a drug is promising in the laboratory, it ultimately has
to be tested in PD patients. This also presents many
obstacles that need to be overcome in identifying a neuro-
protective agent for PD.There are few targets that can be assessed that reflect
a pathogenic mechanism and all too often one has to
proceed without this information. Problems are further
confounded by the scales that are currently employed in
clinical trials, which have a limited range and are par-
ticularly insensitive to detecting change in the early
stages of the disease. In particular, the UPDRS scale has a
clear “floor effect”, which limits the possibility of measur-
ing improvement in an early, mildly affected population.
These problems could be resolved by the development of
a validated biomarker that could be used to confirm the
diagnosis or to serve as an endpoint to objectively meas-
ure disease progression and drug efficacy. Unfortunately,
no such biomarker currently exists [13,14].Clinical trial design
No drug has yet been established to have a neuroprotec-
tive effect in PD. Several clinical trials of putative neuro-
protective agents have shown positive results; however, it
could not be determined with certainty if the benefit was
due to neuroprotection resulting from potentially con-
founding pharmacologic or regulatory effects of the study
agent [1]. In an attempt to separate an early symptom
from a disease modifying effect, the delayed washout and
delayed start studies have been proposed [15]. The delayed
washout has not been considered for use in PD because of
the ethical and practical issues involved in withdrawing
therapy from PD patients, particularly for the periods of
time necessary to conduct the trial.
The delayed start study [16,17] was employed in the
recent ADAGIO study to try and determine if rasagiline
had neuroprotective effects in PD [18]. Rasagiline 1 mg
per day met all three prescribed primary endpoints con-
sistent with the drug having a disease-modifying effect.
However, the 2 mg dose failed to show a difference
between early and delayed treatment at the end of
period 2. Thus, the results of the study were inconclu-
sive and further studies testing these doses separately
are required to determine which of these results is valid.
While the results of ADAGIO are not definitive, the
study design does provide a method for differentiating
early symptomatic and disease-modifying effects and
should facilitate the investigation of new agents. Another
approach is the long-term simple study, where subjects
are randomised to active treatment or placebo, and then
followed for a prolonged period of time (many years) in
which the physician can manage the patient in any way
they deem to be appropriate. The outcome measure
captures factors related to the development of cumula-
tive disability, such as falling, freezing and dementia in
addition to standard UPDRS scores [19]. A combination
of the delayed start and long-term simple studies offers
assessments of mechanism and clinical significance, and
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tective drug [20].
The future
Fortunately, the outlook is improving and there are
promising new candidate target drugs based on genetic
causes of PD. There are new animal models based on
gene mutations associated with familial forms of PD that
will likely prove more reliable in predicting the results of
promising new therapies in clinical trials. The use of
new study designs, such as the delayed start and long-
term simple studies provide a roadmap for defining a
disease-modifying drug and establishing its clinical
significance. Additionally, new clinical trial methodolo-
gies designed to reduce variability in data and analytic
approaches, such as adaptive design, have facilitated the
more rapid and accurate determination of success or
failure of a study intervention in both learning and
confirming trials.
Treatment of early disease
Levodopa
Levodopa is the gold standard for the treatment of PD,
and no medical or surgical therapy has been shown to
provide superior anti-parkinsonian benefits than can be
achieved with levodopa. However, chronic levodopa
treatment is associated with the development of motor
complications and non-motor complications in the
majority of patients [21]. Unfortunately, it is not still
established how levodopa should be administered in
the early stage (dose, formulation, interval between
doses) in order to minimize the risk of complications.
Indeed, several studies have now shown that continuous
infusion of levodopa, which provides a more continuous
dopaminergic stimulation [22-24] in PD patients who
experience motor complications, is associated with a
reduction in both off time and dyskinesia [25-27]. Accord-
ingly, there has been a search for an oral levodopa
treatment strategy that might mirror the pharmacokin-
etics of a levodopa infusion and provide the benefits of
the medication without motor complications.
Entacapone is an inhibitor of catechol-O-methyl trans-
ferase (COMT) that extends the elimination half-life of
levodopa [28], and thus has the potential to provide more
continuous availability of levodopa [29]. Based on these
considerations, the possibility that levodopa/carbidopa
combined with entacapone (LCE), administered 4 times
daily at 3.5 hour intervals, might reduce the risk of dyskin-
esia compared with levodopa/carbidopa (LC) alone was
tested in a prospective, double-blind trial; this included
745 subjects treated for 134–208 weeks (the STRIDE-PD
study) [30]. The study failed to demonstrate the expected
benefit. Indeed, patients randomised to receive LCE
experienced an increased frequency of dyskinesia incomparison to patients receiving LC alone. Despite this,
we believe the rationale behind the STRIDE-PD remains
solid and there are different explanations for the study
failure. The four daily doses administered every 3.5 hours
do not provide a stable and continuous levodopa plasma
level, even when administered with entacapone. It is
difficult to obtain a good compliance from early non-
fluctuating patients in terms of exact dose timing. Daily
levodopa load was higher in the entacapone–levodopa
group.
While the study failed to meet its primary endpoint,
the data from the STRIDE-PD study were explored to
assess the role of levodopa dose and other risk factors in
the development of dyskinesia and wearing-off in this
relatively long-term, double-blind trial [31]. This has great
importance, as there has been a paucity of double-blind
clinical trials informing the optimal method for introdu-
cing levodopa to PD patients.
Patients were divided into 4 dose groups based on nom-
inal levodopa dose at time of onset of dyskinesia (or
study conclusion if no dyskinesia): Group 1, <400 mg/
day (n = 157); Group 2, 400 mg/day (n = 310); Group
3, >400–600 mg/day (n = 201); Group 4, >600 mg/day
(n = 77). Similar analyses were performed with respect to
wearing-off. Time to onset and frequency of dyskinesia/
wearing-off were compared using Cox proportional
hazards model. A stepwise Cox proportional hazards
model was used to screen predictive factors in a multi-
variate analysis. The risk of dyskinesia in the total
population was increased in a levodopa dose-dependent
manner (p < 0.001). Analysis using levodopa equivalent
doses showed comparable results. A stepwise cox pro-
portional hazards model was used to screen predictive
factors for the emergence of dyskinesia in a multivariate
analysis. Young age at onset of PD was the most import-
ant single explanatory factor. The next most important
factor was the nominal levodopa dose. These factors were
followed by: lower weight, region (North America),
treatment allocation (LCE), female gender and baseline
UPDRS part II score. Risk of wearing-off also increased in
a levodopa dose-dependent manner (p < 0.001). Multivari-
ate analyses showed similar predictors as dyskinesia, but
included baseline UPDRS III, and excluded weight and
treatment allocation.
This study reinforced the concept that the risk of
developing dyskinesia and wearing-off each increased
with higher levodopa doses. Thus physicians should use
the lowest dose of levodopa that will provide satisfactory
clinical control to minimize the risk of dyskinesia and
wearing-off [31].
Dopamine agonists
Dopamine agonists (DAs) have longer plasma elimination
half-lives than levodopa. Their use has therefore been
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delivery. By the late 1980s, ergot-derived DAs (bromocrip-
tine, pergolide, lisuride, and cabergoline) already had an
established role as adjuncts to levodopa in advanced PD
because of their ability to reduce “off” time and, in many
instances, allow a lowering of the levodopa dose, reducing
dyskinesias. Later, the use of oral DAs has moved to
earlier stages of PD [31]. Following early pilot uncon-
trolled observations in PD patients [32-34], the first
levodopa-controlled trials were published in the mid-
1980s, suggesting that patients starting on an agonist had
a lower risk of subsequent motor complications than
those starting on levodopa [35-40]. This consistent finding
thereby changed the standard of care from the primary
use of levodopa to the primary and early use of DAs,
especially in younger-onset patients. By the late 1990s,
ergot DAs had been largely replaced by non-ergot drugs
like ropinirole and pramipexole because of reports of
fibrotic adverse reactions, including cardiac valvular
damage from pergolide and cabergoline [41-43]. Recently,
controlled-release formulations of oral ropinirole [44,45],
pramipexole [46] and transdermal formulations of rotigo-
tine have been developed [47,48], offering the convenience
of a once-daily regimen.
After more than a decade of widespread use of DAs in
early PD, long-term clinical experience has taught us that
the initial innovative and attractive finding of delaying
time to dyskinesia with a DA is far from being the sole
relevant outcome to consider. Indeed, our knowledge has
extended to several other important issues:
 The large-scale use of DAs revealed that these drugs
carry a greater risk than levodopa of previously
unknown or underestimated and potentially
troublesome adverse drug reactions, including
abnormal daytime somnolence [49-52], leg oedema
[53], and impulse control disorders [54-56].
 Levodopa must almost inevitably be added to a DA
to keep control of parkinsonism after a few years of
treatment, although the early use of a DA reduces
the cumulative dose of levodopa and explains the
long-term benefit of DAs on dyskinesia [57-59].
 The long-term disability and quality of life of
patients initially randomised to an agonist or
levodopa do not differ [60], although the impact of
dyskinesia on quality of life can vary greatly from
patient to patient.
 It is now realized that in most PD patients long-term
disability (15 years) is driven by problems, such as falls
or dementia, and these are not influenced by early
treatment with agonists or from other drugs [61].
 Finally, it is also now agreed that there is no clinical
evidence supporting the theoretical rationale to
avoid levodopa because of its potential oxidative“toxicity” toward dopamine neurons [62]. However,
it is recommended to use low doses of levodopa to
avoid motor complications.
Dopamine agonists remain important drugs in the
physician’s armamentarium; however, pros and cons of
their use should be considered and the inappropriate
“levodopa phobia”, raised especially among patients [63],
should be reconsidered. DA agonists can be used as first
line treatment but the dose should be carefully evaluated.
Levodopa can be added to a DA agonist when patients
require it, offering the possibility of giving lower doses of
both drugs. Certainly DA agonists can be added to levo-
dopa instead of increasing the levodopa dose, which
provides further advantages for symptoms that respond
better to dopamine agonists (i.e. depression, apathy) and
for reducing the risk of dyskinesia [59].
MAO-B inhibitors
Selegiline (deprenyl) was the first selective, irreversible
inhibitor of monoamine oxidase type B (MAO-B) used
in the treatment of Parkinson’s disease. Because of its
capacity for interfering with oxidative stress and for
blocking MPTP toxicity [64], selegiline was tested in the
first major trial as a putative disease-modifying agent.
The Deprenyl and Tocopheral Antioxidative Therapy of
Parkinsonism trial (DATATOP) was positive in showing
a significant delay in the need for levodopa treatment in
patients treated with deprenyl versus placebo [65]; it also
illustrated that a mild symptomatic effect in a trial such
as this would confound any neuroprotective interpret-
ation [66]. However, the DATATOP study consolidated
the use of selegiline in the treatment of early PD. The
amphetamine-like metabolites of selegiline raised some
concerns about its safety and mortality was reportedly
increased when selegiline and levodopa were given to-
gether, in comparison to treatment with levodopa alone.
However, a large meta-analysis of 5 long-term studies
and 4 separate studies did not support this conclusion.
Selegiline seems to be generally well tolerated in com-
bination with other drugs [67].
Rasagiline is another MAO-B inhibitor, with different
metabolites than selegiline, to be successfully developed
for PD therapy. From a symptomatic perspective, rasagi-
line 1 mg/day proved to be efficacious as monotherapy
in early PD [68,69]. The good tolerability of rasagiline
and its ease of use (1 dose, once daily, no titration)
makes this drug an appealing option to start therapy in
PD [70]. The current popularity of rasagiline is also
related to the finding that the drug has neuroprotective
properties in vitro [71,72] and was the first putative
disease-modifying agent to be tested with a randomised
delayed-start design in PD [18]. Recently, a pragmatic,
open label randomised trial has been published to
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mine agonists, or monoamine oxidase type B inhibitors
(MAOBI)) for initial treatment, which of these provides
the most effective long-term control of symptoms and
best quality of life for people with early Parkinson’s
disease [73]. The authors found a very small but persistent
benefit for patient-rated mobility scores when treatment
was initiated with levodopa compared with levodopa-
sparing therapy. Furthermore, MAOBI as initial levodopa-
sparing therapy was at least as effective as dopamine
agonists. Recently, in a double-blind control study
(ANDANTE study) [74] rasagiline 1 mg/d provided
statistically significant improvement when added to
dopamine agonist therapy and was well tolerated. This
demonstrates that a combination of DA-agonists and
MAOB inhibitor may offer a better control of symptoms
than monotherapy.
Practical considerations
A patient is defined de novo when he or she has never
been exposed to specific pharmacological treatment. The
definition does not imply the severity of the disease and
even in clinical trials on an early population there are
differences in the severity of the population participating
in the study. In the ADAGIO trial, for example, the mean
UPDRS-total score at baseline was 20.4 (8.5); whereas in
the TEMPO study with the same population, the UPDRS-
total score at baseline was 25.0 (10.8). Within this popula-
tion there is a very large range of severity (see above). In
real life, the majority of patients receive the diagnosis 1–2
years after the appearance of the first motor symptom.
Sometimes the patients are not treated at the first instance
but only when the disease progresses. These variables lead
to the evidence that the de novo population is very hetero-
geneous and the decision about the drug initially has to
take into account the general characteristics of the patient,
such as age, cognitive status, comorbidities, occupation,
and the most affected side (dominant or non-dominant)
but also of the severity of the symptoms and the presence
of non-motor symptoms. For example, fatigue is a very
common symptom of PD [75] and in a recent double-
blind study on an early de novo population, rasagiline
significantly improved fatigue [76].
Guidelines refer to de novo population in general and
sometimes take into account the age but not other
determining factors such as severity. De novo patients
can be classified as mild, moderate or severe; mild being
a patient with UPDRS ≥20 and HY stage 1, moderate
UPDRS 20–30 HY stage 1–2, severe UPDRS >30 HY 2
or more. Additional important aspects are the most
affected side, age and metal status. Combining this infor-
mation, along with the efficacy and safety characteristics
of each drug, the physician can make the right choice
and possibly predict the induced benefit.Today we may also consider a combination of drugs
rather than using a single drug at high dose. Rasagiline can
be successfully combined with DA-agonists and L-dopa,
and L-dopa can be combined with a DA and MAOB. A
combination of drugs may be more or equally effective but
may also reduce the dose of each of them, which minimizes
the risks of side effects.
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